Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 62c; Guides Above Views
February 26, 2019 4:10 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $3.64, $0.62 better than the analyst estimate of $3.02. Revenue for the quarter came in at $476.5 million versus the consensus estimate of $459.72 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2019 EPS of $14.30-$15.00, versus the consensus of $13.98.... More
